FMCG Stock Below Rs 5 Surge Amid Fundraising Plans And Recent Business Moves; Do You Own?

Evexia Lifecare, a penny stock, saw its shares rise today following the company's announcement of an upcoming board meeting to discuss fundraising efforts. The company's board of directors will meet on Monday, September 16, 2024, to consider raising funds through the issuance of Convertible Equity Warrants or Equity Shares on a preferential basis. This move is subject to approval from the company's members and necessary regulatory bodies.

In the exchange filing, the company also disclosed that in compliance with SEBI's Insider Trading Regulations (2015), the trading window for Evexia Lifecare shares will remain closed starting September 11, 2024, until 48 hours after the board meeting concludes. During this period, insiders, including promoters, directors, connected persons, and their immediate family members, will be prohibited from trading in the company's shares.

Evexia Lifecare's stock rose by 1.5% today, reaching Rs 3.50 per share, up from the previous closing of Rs 3.46. Over the past year, the stock has seen a high of Rs 3.54 and a low of Rs 1.55, reflecting both volatility and growth potential.

The company has been on an upward trajectory with strong financial results reported in recent quarters. In June 2024, Evexia Lifecare reported standalone net sales of Rs 20.42 crore, marking a 45.65% increase compared to Rs 14.02 crore in June 2023. The company's quarterly net profit surged by an impressive 253.68%, reaching Rs 0.26 crore in June 2024, compared to Rs 0.07 crore in the same period last year. Similarly, its EBITDA rose by 130% to Rs 0.46 crore, up from Rs 0.20 crore in June 2023. Earnings per share (EPS) also saw a significant increase, growing from Rs 0.01 in June 2023 to Rs 0.03 in June 2024.

Evexia Lifecare has been making strides not only financially but also through strategic business moves. In July 2024, the company held a board meeting to approve the conversion of 25 Foreign Currency Convertible Bonds (FCCBs) into equity shares. This decision followed the approval of FCCBs during the company's Annual General Meeting in July 2022. The conversion is part of the company's broader plan to optimize its capital structure and drive growth.

In May 2024, Evexia Lifecare took another significant step by acquiring an 80% stake in Revin Labs Pvt. Ltd., a company specializing in analytical testing services for pharmaceuticals. The acquisition, valued at Rs 44.8 crore, was settled through a mix of cash (Rs 22.4 crore) and equity shares issued to Revin Labs' shareholders at Rs 140 per share. This acquisition aligns with Evexia's strategy to expand into high-growth sectors such as pharmaceuticals and analytical services, reinforcing its commitment to innovation and diversification.

Formerly known as Kavit Industries Limited, Evexia Lifecare has evolved significantly. Initially engaged in the trading of chemicals, agricultural produce, and various consumer goods, the company has expanded its footprint into more specialized sectors. Its product offerings now include petrochemical downstream products such as specialized oils, chemicals, petroleum sulphates, and solvents used in industries like rubber, leather, ink, and paint.